Skip to main content

Table 3 Trials of 2 nd generation TKI in acquired resistance setting

From: Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer

 

N

OR%

mPFS (mo)

mOS (mo)

Afatinib

    

LUX LUNG I trial 40

    

Afatinib

390

7

3.3

10.8

Placebo

195

<1

1.1

12.0

LUX LUNG IV trial 42

61

8.2

4.4

19

XL647

    

Phase II trial52

41

3

3.6

16.1

  1. <, less than.